TRex Bio, Inc.
TRex Bio is a biotechnology company based in South San Francisco, California, developing biologic medicines for autoimmune and inflammatory diseases. Its Deep Biology Platform combines human tissue analysis, studies of regulatory T cells, and functional assays to discover and validate therapeutic targets. The company’s programs include TRB-061, designed to activate and expand regulatory T cells in inflamed tissues; TRB-071, intended to support tissue regulatory T cells and inhibit inflammatory signaling; and TRB-051, a partnered immune effector cell modulator.
Stifel initiated coverage on TRex Bio (NASDAQ:TRXB) with a buy rating and $39 price target. The stock trades at $13.64, near its 52-week low. Stifel highlights potential in Treg therapy for autoimmune diseases, citing TRex Bio's pipeline, including TRB-061 and a partnership with Eli Lilly.
Wedbush initiated coverage of Trex Bio with an Outperform rating and a $30 price target, implying 118.3% upside from the Oct 30 close of $13.74, according to the firm.
SV Biotech Crossover Opportunities Fund LP acquired a 7.0% stake in TRex Bio, Inc. (TRXB), buying 957,143 shares in the Oct. 2026 IPO and converting 963,524 preferred shares. The fund may engage with TRex Bio's leadership or other shareholders to propose changes or buy/sell more shares. A 180-day IPO lock-up restricts sales. SV Biotech focuses on life sciences investing.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning TRXB (TRex Bio, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent TRXB coverage spans financial news, insider activity and corporate actions.
In the last 30 days, TRXB insiders filed 3 SEC Form 4 transactions — 3 purchases ($3.8M) and no sales. The most active reporter was SVLSF VI, LLC with 2 filings.
Analyst initiation and elevated price target suggest upside potential.
Wedbush initiated coverage of Trex Bio with an Outperform rating and a $30 price target, implying 118.3% upside from the Oct 30 close of $13.74, according to the firm.
The new large shareholder may influence governance and future capital actions.
The filing signals a 10% owner adding shares at $14.00, which can be read as support but is not a fundamental catalyst by itself.
The governance update may improve investor confidence but has limited immediate price impact.
AlphAI scores every news story that mentions TRXB with an AI model for sentiment and relevance, and aggregates insider trades from TRex Bio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stifel initiated coverage on TRex Bio (NASDAQ:TRXB) with a buy rating and $39 price target. The stock trades at $13.64, near its 52-week low. Stifel highlights potential in Treg therapy for autoimmune diseases, citing TRex Bio's pipeline, including TRB-061 and a partnership with Eli Lilly.
2 min readWedbush initiated coverage of Trex Bio with an Outperform rating and a $30 price target, implying 118.3% upside from the Oct 30 close of $13.74, according to the firm.
1 min readSV Biotech Crossover Opportunities Fund LP acquired a 7.0% stake in TRex Bio, Inc. (TRXB), buying 957,143 shares in the Oct. 2026 IPO and converting 963,524 preferred shares. The fund may engage with TRex Bio's leadership or other shareholders to propose changes or buy/sell more shares. A 180-day IPO lock-up restricts sales. SV Biotech focuses on life sciences investing.
1 min readAlexandria Venture Investments, LLC purchased 178,571 shares of TRex Bio, Inc. (TRXB) at $14.00 ($2.50M total) on 2026-10-13.
2 min readTRex Bio, Inc. (TRXB) updated its governance structure post-IPO, authorizing 225M common and 25M preferred shares, and removing written consent for stockholder actions. The changes align with public-company standards and include updated bylaws for proposals, director nominations, and indemnification. The company aims for broader capital market access with a market cap of $385.1M.
1 min readTRex Bio Inc. (TRXB) raised $116.7 million from its IPO, selling 8.33 million shares at $14 each. The offering was led by J.P. Morgan, Evercore ISI, Cantor, and Stifel. The company focuses on immunoregulatory medicines for autoimmune and inflammatory diseases.
1 min readSVLSF VI, LLC purchased 92,857 indirectly-held shares of TRex Bio, Inc. (TRXB) at $14.00 ($1.30M total) across 2 trades on 2026-10-08. Filed jointly with SV Life Sciences Fund VI (GP), L.P. (10% owner) and SV Life Sciences Fund VI, L.P. (10% owner).
1 min read
